Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9542124 | 0.86 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL9542871 | 0.82 | ALDH1A1 (0.43) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL8803147 | 0.78 | MAPT (0.46) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL7801786 | 0.78 | ALDH1A1 (0.45) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL4269080 | 0.77 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL3469591 | 0.77 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL8594839 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| Hydrochloric Acid SCHEMBL4618823 | 0.74 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2GAAMDM2 | |
| SCHEMBL3986231 | 0.74 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL8663859 | 0.73 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273974-A2 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | Tolmar, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137100-A2 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | TOLMAR, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | MARTON MILANKOVITS | 2009-05-14 | — | — | US | disclosed |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | MILANKOVITS MARTON | 2009-03-19 | — | — | US | disclosed |
| WO-1993020817-A1 | NOVEL USE OF NITROIMIDAZOLES | HYDRO PHARMA SVERIGE AB (SE) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | SOD1, OAT, ELANE | MAPT 252/4885ALDH1A1 1707/4885SMN1; SMN2 4/4885 |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | DHFR, FPGS, FOLR1 | MAPT 1948/4885ALDH1A1 4171/4885SMN1; SMN2 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.